4.3 Article

Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?

期刊

CURRENT DIABETES REPORTS
卷 14, 期 1, 页码 -

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-013-0453-1

关键词

AGE-receptors; AGER1; SIRT1; Glycation; Oxidation; Diet; Inflammation; Innate immunity

资金

  1. National Institutes of Health, National Institute of Research Resources [M01-RR-00071]
  2. [AG-23188]
  3. [AG-09453]
  4. NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK091231] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE ON AGING [R01AG009453, R37AG023188] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Despite new and effective drug therapies, insulin resistance (IR), type 2 diabetes mellitus (T2D) and its complications remain major medical challenges. It is accepted that IR, often associated with over-nutrition and obesity, results from chronically elevated oxidant stress (OS) and chronic inflammation. Less acknowledged is that a major cause for this inflammation is excessive consumption of advanced glycation end products (AGEs) with the standard western diet. AGEs, which were largely thought as oxidative derivatives resulting from diabetic hyperglycemia, are increasingly seen as a potential risk for islet beta-cell injury, peripheral IR and diabetes. Here we discuss the relationships between exogenous AGEs, chronic inflammation, IR, and T2D. We propose that under chronic exogenous oxidant AGE pressure the depletion of innate defense mechanisms is an important factor, which raises susceptibility to inflammation, IR, T2D and its complications. Finally we review evidence on dietary AGE restriction as a nonpharmacologic intervention, which effectively lowers AGEs, restores innate defenses and improves IR, thus, offering new perspectives on diabetes etiology and therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据